These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 2565604)
1. The neu (c-erbB-2) oncogene. Maguire HC; Greene MI Semin Oncol; 1989 Apr; 16(2):148-55. PubMed ID: 2565604 [TBL] [Abstract][Full Text] [Related]
2. [Proto-oncogene C-erbB-2 and human cancer]. Toyoshima K Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):309-14. PubMed ID: 1968737 [TBL] [Abstract][Full Text] [Related]
3. [Amplification of the erbb-2 (Her-2/NEU), erbb-1 (HER-1) and c-myc oncogenes is often combined with the deletion of the short arm of chromosome 17 in human carcinoma]. Imianitov EN; Chernitsa OI; Nikiforova IF; Serova OM; Sokolov SI; Laur OIu; Togo AV; Kniazev PG Mol Biol (Mosk); 1993; 27(4):888-94. PubMed ID: 8103188 [TBL] [Abstract][Full Text] [Related]
4. Neu (c-erbB-2), a tumor marker in carcinoma of the female breast. Maguire HC; Greene MI Pathobiology; 1990; 58(6):297-303. PubMed ID: 1981830 [TBL] [Abstract][Full Text] [Related]
5. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. van de Vijver M; van de Bersselaar R; Devilee P; Cornelisse C; Peterse J; Nusse R Mol Cell Biol; 1987 May; 7(5):2019-23. PubMed ID: 3299059 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model. Hal DG; Stoica G Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494 [TBL] [Abstract][Full Text] [Related]
8. Early mutation of the neu (erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage. Nikitin AYu ; Ballering LA; Lyons J; Rajewsky MF Proc Natl Acad Sci U S A; 1991 Nov; 88(22):9939-43. PubMed ID: 1682925 [TBL] [Abstract][Full Text] [Related]
10. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395 [TBL] [Abstract][Full Text] [Related]
11. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867 [TBL] [Abstract][Full Text] [Related]
12. Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. Knyazev PG; Imyanitov EN; Chernitca OI; Nikiforova IF; Hanson KP Oncology; 1992; 49(2):162-5. PubMed ID: 1349430 [TBL] [Abstract][Full Text] [Related]
13. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018 [TBL] [Abstract][Full Text] [Related]
14. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Yokota J; Yamamoto T; Miyajima N; Toyoshima K; Nomura N; Sakamoto H; Yoshida T; Terada M; Sugimura T Oncogene; 1988 Mar; 2(3):283-7. PubMed ID: 3281095 [TBL] [Abstract][Full Text] [Related]
15. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702 [TBL] [Abstract][Full Text] [Related]
17. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Singleton TP; Strickler JG Pathol Annu; 1992; 27 Pt 1():165-90. PubMed ID: 1346551 [TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965 [TBL] [Abstract][Full Text] [Related]
19. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Williams TM; Weiner DB; Greene MI; Maguire HC Pathobiology; 1991; 59(1):46-52. PubMed ID: 1675057 [TBL] [Abstract][Full Text] [Related]
20. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Gaffey MJ; Frierson HF; Williams ME Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]